Global stock

ASXAUD

CSL Limited

CSL.AX

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

64/ 100

Overall score·CSL.AX

Current price

196.22AUD

27/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E kolem 16.6 a EV/EBITDA kolem 15.9 naznačují, že akcie mohou být vůči sektoru na nižším násobku a mírně podhodnocené. Nízké EPS YoY (-80.1%) a meziroční růst tržeb (-1.8%) ukazují na riziko slabé ziskovosti, zatímco PEG 1.82 a P/B 2.89 naznačují rozumné ocenění vzhledem k očekávanému růstu. Trend smeruje k nejistotě ohledně ziskovosti, i když nedávné zprávy o vakcíně a akvizice mohou cenu posunout výše v krátkém horizontu.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 53%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Context and events

Management

CEO, výkonným ředitelem a členem představenstva je Gordon Naylor; finančním ředitelem Ken Lim a provozní ředitelkou Mary Oates. Strategie společnosti stojí na rozvoji léčiv z krevní plazmy, vakcín a biologických přípravků a na efektivním provozu globální sítě odběrových center.

Articles about CSL Limited, in Czech (0)

No articles yet. New analyses are published daily.

§ Frequently asked questions

What is CSL Limited (CSL.AX)?

CSL Limited (CSL.AX) is a global stock traded on ASX. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the CSL Limited price today?

As of 27 October 2026, CSL Limited trades at about 196.22 AUD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy CSL Limited?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does CSL Limited pay a dividend?

CSL Limited either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is CSL Limited a good investment in 2026?

Our AI signal currently rates CSL Limited as slightly positive (score 59/100). Financial health comes out at 64/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy CSL Limited

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

News summary

Fresh news

Signal 27/10, 10:01

CSL má podle zprávy zítra zveřejnit výsledky; pozitivní překvapení by mohlo podpořit růst, slabý výhled jej naopak zvrátit.

Cena za 30 dní vzrostla o 10,09 % a trend je rostoucí, ale RSI 73 značí překoupenost a volatilita je vysoká. Výsledky mohou směr výrazně změnit.

Risks: Slabší výsledky či výhled, případně obrat rostoucího trendu, by oslabily současný pozitivní cenový signál.

More about the signal

Cena za 30 dní vzrostla o 10,09 % a trend je rostoucí, ale RSI 73 značí překoupenost a volatilita je vysoká. Výsledky mohou směr výrazně změnit.

Risks: Slabší výsledky či výhled, případně obrat rostoucího trendu, by oslabily současný pozitivní cenový signál.

Signal history· 2

02/1017:0162 · Slightly positive
CSL zůstává stabilní na trhu, signály makroekonomické situace a technické indikátory naznačují stabilitu s mírným nádechem růstu.
28/0910:0185 · Strongly positive
Technologický sektor a AI pivot firmy CSL stimuluje pozitivní náladu; technická výkonnost podporuje uptrend, RSI nad 70 signálují silné momentum v krátkém horizontu.

The full 90-day signal history is part of Premium.

Ask the AI

DCF valuation

A DCF model is not suitable for this asset class.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 17 of 18

Valuation score

1/ 6

4/6 tests available

1. Below DCF fair value

The complete DCF range or the current price is missing.

2. Well below DCF value

The complete DCF range or the current price is missing.

3. Price vs. the last year

100% above the 1-year low (92.24 AUD to 196.7 AUD), based on stored daily prices.

4. P/E vs. similar companies

P/E 18.1 vs. median 26.7 (71 companies).

5. P/E relative to growth

PEG 1.8; a lower value means cheaper growth.

6. Analyst price target

-30.2% vs. the current price, 16 analysts.

Price and fair value

no complete range

The DCF check appears once both the price and the model range are available.

Price vs analyst target

Current price

196.2 AUD

Low 106.5 AUDHigh 195.1 AUD

Current priceAverage: 136.9 AUD

DCF gap

no complete range

The DCF check appears once both the price and the model range are available.

Analyst target

-30.2%

Average target 136.9 AUD vs. price 196.2 AUD.

Analyst consensus

Target range

106.5 AUD - 195.1 AUD

Coverage

16 analysts

Analyst consensus

2.3 / 5

Changes 180 d

+0 / -0

EPS next year

6.0%

Revenue next year

3.8%

Valuation multiples

18.1

16.6

2.9

15.9

1.8

52-week range100% above the low

92.24 AUD196.7 AUD

-80.0%

-2.0%

9.1%

6.7%

Price vs 50D62.8%

Price vs 200D36.7%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 27/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení je průměrné, s stabilní exekucí a smysluplnými kroky v alokaci kapitálu (nová vakcína, akvizice), avšak některé prvky odměňování vyvolávají pochybnosti.

strong

Moat je středně silný díky rozsahu portfolia, IP a regulačnímu vstupu, ale závislost na pipeline a konkurenční tlak mohou tuto výhodu limitovat.

Information

Type: Global stock
Symbol: CSL.AX
Exchange: ASX
Currency: AUD
Sector: Healthcare
: 18.1x
: 54.4 %
: 0.09

§ Risk profile

Výsledky mohou ovlivnit regulatorní zásahy, náklady a dostupnost plazmy, konkurence i neúspěch klinického vývoje. Český investor navíc nese měnové riziko australského dolaru.

Ask the AI about CSL Limited All signals